Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients

NCT ID: NCT02297763

Last Updated: 2014-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

194 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of low dose quetiapine for the prophylaxis of delirium in critically ill patients in medical intensive care unit.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delirium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

quetiapine

quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.

Group Type ACTIVE_COMPARATOR

quetiapine

Intervention Type DRUG

patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg

quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.

The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water).

placebo

The placebo is made of 100mg of corn starch which is melted in 10cc water.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

The placebo is made of 100mg of corn starch which is melted in 10cc water.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

quetiapine

patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg

quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.

The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water).

Intervention Type DRUG

placebo

The placebo is made of 100mg of corn starch which is melted in 10cc water.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Greater than or equal to 19 years of age, admitting to medical ICU, anticipated to stay more than 72hours

Exclusion Criteria

* Female patients who are pregnant or breastfeeding
* active delirium
* Received other anti-psychotic drug before attend the study
* severe bradycardia
* alcohol intoxication
* No written consent from the legal representatives
* Being ill with renal or hepatic failure
Minimum Eligible Age

19 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

YJLSM2014

Identifier Type: -

Identifier Source: org_study_id